Persistent viral eradication or suppression through a defined course of Pegylated-interferon (PegIFN) or the administration of a long-term potent nucleot(s)ide analogues (NUCs) can impact positively the natural course of HBV infection by preventing disease progression. Despite the higher rates of off-therapy response achieved with PegIFN compared with NUC, its benefits are restricted to a subgroup of patients only. To increase the rates of patients who may benefit from PegIFN treatment, minimizing the adverse events, careful patient selections based on baseline features and on treatment HBsAg kinetics for individual treatment optimization are required.

Results of treatment of chronic hepatitis B with pegylated interferon / M. Viganò, G. Mangia, P. Lampertico. - In: CLINICS IN LIVER DISEASE. - ISSN 1089-3261. - 17:3(2013), pp. 425-443. [10.1016/j.cld.2013.05.004]

Results of treatment of chronic hepatitis B with pegylated interferon

M. Viganò
Primo
;
G. Mangia
Secondo
;
P. Lampertico
2013

Abstract

Persistent viral eradication or suppression through a defined course of Pegylated-interferon (PegIFN) or the administration of a long-term potent nucleot(s)ide analogues (NUCs) can impact positively the natural course of HBV infection by preventing disease progression. Despite the higher rates of off-therapy response achieved with PegIFN compared with NUC, its benefits are restricted to a subgroup of patients only. To increase the rates of patients who may benefit from PegIFN treatment, minimizing the adverse events, careful patient selections based on baseline features and on treatment HBsAg kinetics for individual treatment optimization are required.
Chronic hepatitis B; HBsAg levels; HBV DNA; IL28B polymorphism; Pegylated interferon; Sustained response; Antiviral Agents; Clinical Trials as Topic; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Patient Selection; Precision Medicine; Treatment Outcome; Hepatology
Settore MED/12 - Gastroenterologia
2013
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S108932611300024X-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.15 MB
Formato Adobe PDF
1.15 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/437676
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact